Kore Liow, MD
Neurology · Honolulu, HINPI 1366445306
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,466 of the $14,897 with a category attached, or 77.0%. It is spread thinly across 54 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $4,696, 4.3 times the $1,080 reported in 2019.
Across 456 payments — averaging $32.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- UCB SA$3K
- Eisai Inc.$1K
- F. Hoffmann-la Roche AG$805
- Novartis$756
- SK Life Science, Inc.$625
- plus $6K from 48 others
Across 1,011 payments — averaging $7940.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$1.7M
- Novartis$1.6M
- Eli Lilly$626K
- UCB SA$595K
- Novo Nordisk AS$488K
- Eisai Inc.$456K
- plus $2.6M from 23 others
What the payments were for
- Consulting fees$7255%
- Speaking & faculty fees$2,52517%
- Food & beverage$11,46677%
- Education$1821%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,897 in reported general payments places this provider in the 85th percentile of 54 neurology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 19 | $275,291 |
| ValtocoDiazepam | 30 | $66,770 |
| BotoxOnabotulinumtoxina | 18 | $22,890 |
| BriviactBrivaracetam | 12 | $18,264 |
| XcopriCenobamate | 13 | $18,083 |
| QuliptaAtogepant | 15 | $16,110 |
| FycompaPerampanel | 12 | $14,042 |
| Levetiracetam | 166 | $7,161 |
| Lacosamide | 75 | $6,485 |
| Memantine Hcl | 111 | $5,259 |
| Rivastigmine | 29 | $3,919 |
| Lamotrigine | 109 | $3,601 |
| Donepezil Hcl | 210 | $3,382 |
| Oxcarbazepine | 18 | $2,193 |
| Lamotrigine ErLamotrigine | 14 | $2,118 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $92 | $275,29119 claims |
| Neurelis, Inc.Valtoco | $411 | $66,77030 claims |
| AbbVieBotox, Qulipta | $2,919 | $38,99933 claims |
| UCB, Inc.Briviact | $268 | $18,26412 claims |
| SK Life Science, Inc.Xcopri | $625 | $18,08313 claims |
| Eisai Inc.Fycompa | $1,109 | $14,04212 claims |
| Upsher-smith Laboratories LLCTopiramate | $20 | $58938 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 54 neurology providers in Hawaii.
Other neurology in Honolulu
- Leo MaherHonolulu$382K
- Leah RidgeHonolulu$47K
- Melvin YeeHonolulu$32K
- Kevin KimataHonolulu$24K
- Terry ShimamotoHonolulu$24K
- Michael RussoHonolulu$20K
- Fay GaoHonolulu$13K
- Sarah GranerHonolulu$10K
- Jeffrey LiuHonolulu$8K
- Monique CanonicoHonolulu$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.